A single-arm, prospective, open-label clinical study of camrelizumab combined with apatinib mesylate as a third-line treatment for advanced colorectal cancer
收藏NIAID Data Ecosystem2026-03-11 收录
官方服务：
资源简介：
Interventions: single arm:camrelizumab combined with apatinib mesylate Primary outcome(s): PFS Study Design: Single arm
创建时间：
2020-02-15
